Long-term methotrexate therapy for rheumatoid arthritis

Seminars in Arthritis and Rheumatism

Volumn 20, Issue 5, 1991, Pages 317-331

  Scully, Christopher J ^a   Anderson, Cynthia J ^a   Cannon, Grant W ^a  

^a NONE

Author keywords

cytotoxic drugs; methotrexate; Rheumatoid arthritis

Indexed keywords

METHOTREXATE;

ADULT; ALOPECIA; ARTICLE; DIAGNOSIS; FEMALE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RASH; RHEUMATOID ARTHRITIS; STOMATITIS;

ADULT; AGED; ARTHRITIS, RHEUMATOID; BIOPSY; BLOOD CELL COUNT; FEMALE; HUMAN; LIVER; MALE; METHOTREXATE; MIDDLE AGE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.; TIME FACTORS;

EID: 0025784932     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/0049-0172(91)90032-U     Document Type: Article

References (120)

1. A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis
2. Weekly pulse methotrexate in rheumatoid arthritis: Clinical and immunologie effects in a randomized, double-blind study
3. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis: A controlled clinical trial
4. Efficacy of low-dose methotrexate in rheumatoid arthritis
5. Low-dose methotrexate compared with azathioprine in the treatment of rheumatoid arthritis: A 24 week controlled clinical trial
6. A double blind comparative study of azathioprine and methotrexate in patients with rheumatoid arthritis (RA) Preliminary results
7. Gold sodium thiomalate compared to low dose methotrexate in the treatment of rheumatoid arthritis—A randomized, doubleblind 26-week trial
8. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis
9. Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis: A thirty-six-week double-blind
10. Weekly intravenous methotrexate in the treatment of rheumatoid arthritis
11. A randomized controlled trial of parenteral methotrexate compared with sodium aurothiomalate (Myochrysine) in the treatment of rheumatoid arthritis
12. Low dose methotrexate in rheumatoid arthritis
13. Low dose pulse methotrexate therapy in rheumatoid arthritis
14. Methotrexate therapy in rheumatoid arthritis 15 years experience
15. Low-dose methotrexate treatment of rheumatoid arthritis. Long-term observations
16. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis
17. Low-dose weekly oral methotrexate therapy for inflammatory arthritis
18. Pulse methotrexate therapy in rheumatoid arthritis: A controlled prospective roentgenographic study
19. A long-term prospective study of the use of methotrexate in rheumatoid arthritis. Update after a mean of fifty-three months
20. Long-term methotrexate in rheumatoid arthritis
21. Methotrexate in rheumatoid arthritis Toxic effects as the major factor in limiting long-term treatment
22. Toxicity of methotrexate compared with azathioprine in the treatment of rheumatoid arthritis. A case-control study of 131 patients
23. Prospective long term follow-up of methotrexate therapy in rheumatoid arthritis: Toxicity, efficacy and radiological progression
24. Low-dose methotrexate treatment of rheumatoid arthritis; long-term observation of efficacy and safety
25. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: A 14-year prospective evaluation of 1017 consecutive starts
26. Length of time on slow acting anti-rheumatic drugs (SAARDS): Evidence for methotrexate effectiveness
27. Incidence of untoward reactions in patients with rheumatoid arthritis treated with methotrexate
28. Significant methotrexate (MTX) toxicity in RA patients: Results of an ongoing long-term prospective trial
29. Twenty year experience of methotrexate (MTX) toxicity in rheumatoid arthritis (RA)
30. Methotrexate therapy in rheumatoid arthritis: Two year retrospective follow-up study
31. Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis
32. Low dose oral methotrexate in rheumatoid arthritis: An uncontrolled trial and review of the literature
33. Proposed diagnostic criteria for rheumatoid arthritis
34. Hepatic fibrosis is the only lesion characteristic of methotrexate treatment in rheumatoid arthritis
35. Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate
36. Acute lung disease associated with low-dose pulse methotrexate therapy in patients with rheumatoid arthritis
37. Methotrexate is significantly more likely to be continued over two years than gold salts penicillamine or hydroxychloroquine in rheumatoid arthritis
38. Comparison of methotrexate with azathioprine or 6-mercaptopurine in refractory rheumatoid arthritis: A life-table analysis
39. Low dose pulse methotrexate in rheumatoid arthritis: An 8 year experience with hepatotoxicity
40. Studies on the frequency and pathogenesis of liver involvement in rheumatoid arthritis
41. Clinical associations between arthritis and liver disease
42. Pretreatment liver histology in rheumatoid arthritis (RA) patients treated with low dose methotrexate (MTX)
43. Prospective analysis of liver biopsies before and after methotrexate therapy in rheumatoid patients
44. Methotrexate associated hepato-toxicity with long term treatment of rheumatoid arthritis
45. Acute reversible hepatic failure associated with methotrexate treatment of rheumatoid arthritis
46. Hepatitis with bridging fibrosis and reversible hepatic insufficiency in a woman with rheumatoid arthritis taking methotrexate
47. Methotrexate induced cirrhosis requiring liver transplantation in three patients with psoriasis: a word of caution in light of the expanding use of this “steroid sparing” agent
48. Liver injury associated with methotrexate therapy for psoriasis
49. Liver biopsies from psoriatics related to methotrexate therapy
50. Methotrexate hepatotoxicity in psoriasis. Consideration of liver biopsies at regular intervals
51. Methotrexate induced liver cirrhosis. Studies including serial liver biopsies during continued treatment
52. Low incidence of hepatotoxicity associated with long-term, low dose oral methotrexate in treatment of refractory psoriasis, psoriatic arthritis, and rheumatoid arthritis. An acceptable risk/benefit ratio
53. Methotrexate-associated hepatotoxicity: Retrospective analysis of 210 patients with rheumatoid arthritis
54. Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy
55. Methotrexate and the liver
56. Histopathologic findings in the liver of rheumatoid arthritis patients treated with long-term bolus methotrexate
57. Liver histology in patients receiving low dose pulse methotrexate for the treatment of rheumatoid arthritis
58. Hepatotoxicity of prolonged methotrexate therapy for rheumatoid arthritis
59. Hepatic ultrastructure after methotrexate therapy for rheumatoid arthritis
60. Liver biopsies v liver scans in methotrexate-treated patients with psoriasis
61. Ultrasound as a screening procedure for methotrexate-induced hepatic damage in severe psoriasis
62. Comparison of liver scans and liver biopsies in patients with psoriasis
63. Methotrexate induced liver abnormalities in rheumatoid arthritis
64. Liver biopsy findings in patients with rheumatoid arthritis undergoing longterm treatment with methotrexate
65. Methotrexate and liver biopsies. Is it really necessary?
66. Toxicity to methotrexate in rheumatoid arthritis
67. Methotrexate-associated, early-onset pancytopenia in rheumatoid arthritis
68. Pancytopenia associated with low dose pulse methotrexate in the treatment of rheumatoid arthritis
69. Pancytopenia induced by low-dose methotrexate for rheumatoid arthritis
70. Fatal interaction between methotrexate and naproxen
71. Methotrexate-associated bone marrow suppression following surgery
72. Megaloblastic pancytopenia in a patient receiving concurrent methotrexate and trimethoprim-sulfamethoxazole treatment
73. Methotrexate toxicity in a patient receiving trimethoprim-sulfamethoxazole
74. Methotrexate toxicity in a patient receiving trimethoprim-sulfamethoxazole
75. Severe bone marrow failure due to low dose oral methotrexate
76. Cytotoxic drugs: Their clinical application to the rheumatic diseases
77. Methotrexate in rheumatoid arthritis
78. Toxicity of low dose methotrexate in rheumatoid arthritis
79. Accelerated nodulosis and vasculitis during methotrexate therapy for rheumatoid arthritis
80. Eruption of nodulosis and vasculitis during methotrexate therapy for rheumatoid arthritis
81. Leukocytoclastic vasculitis after high-dose methotrexate
82. Smallvessel vasculitis and methotrexate
83. Methotrexate pneumonitis in rheumatoid arthritis Potential risk factors Four case reports and a review of the literature
84. Methotrexate-induced pneumonitis
85. Severe reversible interstitial pneumonitis induced by low dose methotrexate: Report of a case and review of the literature
86. Fatal methotrexate pneumonitis in rheumatoid arthritis
87. Life threatening acute pneumonitis during low dose methotrexate treatment for rheumatoid arthritis: A case report and review of the literature
88. Methotrexateinduced pneumonitis: Appearance four weeks after discontinuation of treatment
89. Methotrexate pneumonitis after low-dose therapy for rheumatoid arthritis
90. Pneumonitis complicating low-dose methotrexate therapy in rheumatoid arthritis
91. Pre-existing lung disease in patients with rheumatoid arthritis (RA) may predispose to methotrexate (MTX) lung
92. Cryptococcosis associated with low-dose methotrexate for arthritis
93. Pneumonitis carinii pneumonia following methotrexate therapy for rheumatoid arthritis
94. Pneumonitis carinii pneumonia complicating low dose methotrexate treatment for psoriatic arthropathy
95. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease
96. Methotrexateinduced congenital malformations
97. Aminopterin and methotrexate: Folic acid deficiency
98. Methotrexate and fertility in men
99. Psoriasis, methotrexate and oligospermia
100. Impotence in three rheumatoid arthritis patients treated with methotrexate
101. Pregnancy after cytotoxic chemotherapy for gestational trophoblastic tumours
102. Pregnancy outcome following cancer chemotherapy
103. Congenital anomalies among children born of mothers receiving chemotherapy for gestational trophoblastic neoplasms
104. Thymoma associated with rheumatoid arthritis in a patient taking methotrexate
105. Malignancy during methotrexate and steroid therapy for psoriasis
106. Methotrexate-induced carcinoma
107. Is methotrexate therapy for psoriasis carcinogenic? A modified retrospective analysis
108. No increase in second tumors after cytotoxic chemotherapy for gestational trophoblastic tumors
109. Clinical and pharmacokinetic evidence of a life threatening interaction between methotrexate and ketoprofen
110. Effect of oral prophylactic board spectrum nonabsorbable antibiotics on the gastrointestinal absorption of nutrients and methotrexate in small cell bronchogenic cancer
111. Increased methotrexate toxicity due to concurrent probenecid administration
112. Plasma protein binding of methotrexate and its displacement by various drugs
113. Comparison of toxicity in methotrexate (MTX) treated rheumatoid arthritis (RA) patients also taking aspirin of other NSAID
114. Transient neurologic dysfunction following moderate-dose methotrexate for undifferentiated lymphoma
115. Transient neurologic disturbances induced by high-dose methotrexate treatment
116. Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia
117. Central nervous system toxicity associated with weekly low-dose methotrexate treatment
118. Renal toxicity of methotrexate
119. Accidental kidney biopsies in psoriasis